Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.
about
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Vemurafenib-resistance via de ...... roid carcinoma with BRAFV600E.
@en
Vemurafenib-resistance via de ...... roid carcinoma with BRAFV600E.
@nl
type
label
Vemurafenib-resistance via de ...... roid carcinoma with BRAFV600E.
@en
Vemurafenib-resistance via de ...... roid carcinoma with BRAFV600E.
@nl
prefLabel
Vemurafenib-resistance via de ...... roid carcinoma with BRAFV600E.
@en
Vemurafenib-resistance via de ...... roid carcinoma with BRAFV600E.
@nl
P2093
P2860
P356
P1433
P1476
Vemurafenib-resistance via de ...... roid carcinoma with BRAFV600E.
@en
P2093
Agnes S Lo
Carmelo Nucera
Christine R Bryke
Giovanni Roti
Mukta Joshi
Paul Van Hummelen
S Ananth Karumanchi
P2860
P304
84743-84760
P356
10.18632/ONCOTARGET.21262
P407
P577
2017-09-24T00:00:00Z